Permits and Restrictions |
View Permits View Restrictions |
---|---|
Organism | Homo sapiens, human |
Components | ATCC CCL-225 HCT-15 ATCC CCL-237 SW948 ATCC CRL-1739 AGSATCC CRL-2577 RKOATCC HTB-112 HEC-1-AATCC HTB-121 BT-483ATCC HTB-131 MDA-MB-453ATCC HTB-178 NCI-H596ATCC HTB-19 BT-20ATCC HTB-27 MDA-MB-361 |
Applications | This panel is useful for PI3K pathway research and for anti-cancer drug discovery. |
Biosafety Level |
2 [Cells contain Parainfluenza virus type 5]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Comments |
The Phosphoinositide 3‑kinases (PI3Ks) family of enzymes is integral to several signaling pathways that mediate cell proliferation, survival, migration and vesicular trafficking. Member of the PI3K family are frequently mutated or altered in human cancers. For example, gain-of-function mutations in p110α (encoded by the PI3KCA gene) are observed in a variety of common cancers; and, these mutations are exclusively clustered in one of two hotspot regions, (i.e., exon 9 and 20), which correspond to either the helical or kinase domains of the protein (e.g., E545K and H1047R). The PI3K Genetic Alteration Cell Panel (ATCC TCP-1028) is composed of ten human tumor cell lines from common cancer types that carry hotspot mutations within the PIK3CA gene. The PI3KCA status of each cell line has been sequenced and validated by ATCC. This panel is useful for PI3K pathway research and for anti-cancer drug discovery. |
Product Format | frozen |
Storage Conditions | LN vapor (less than -130°C) only |
Permits |
These permits may be required for shipping this product to Australia:
|
---|---|
Basic Documentation | Product Sheet Certificate of Analysis SDS |
Other Documentation | Recommended Culture Conditions Genetic Alteration Panels - Brochure |
Restrictions |
Unless the Purchaser has a separate license agreement with The University of Texas M. D. Anderson Cancer Center (“Institution”), the ATCC Material is subject to the following restrictions:
The restrictions set forth above are in addition to the restrictions set forth in the ATCC Material Transfer Agreement. Capitalized terms have the meanings set forth in the ATCC Material Transfer Agreement unless otherwise indicated above. For instructions on how to obtain a license from Institution, please contact Dustin J. Romine, M.A. at the Institution Office of Technology Commercialization via email at dromine@mdanderson.org. Purchaser acknowledges and agrees that ATCC will send Purchaser’s contact information and order details to Institution’s Office of Technology Commercialization. |